New Yescarta Ph3 Trial (ZUMA-23) for 1L LBCL Posted
Here is a brief preview of this blast: On Friday, November 4, a new Kite-sponsored Ph3 trial (ZUMA-23) evaluating Yescarta (Gilead / Kite’s CD19 CAR-T) in 1L high-risk LBCL was observed on CT.gov. Below, Celltelligence provides details for the trial while discussing Yescarta’s potential to displace the current SOC in 1L LBCL.